Business
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 2, 2021
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a
About this update from Aptorum Group Limited
[{"type":"text","content":" NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--\nRegulatory News:\n\nAptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, announced that it will hold its 2021 annual general meeting of shareholders at Meeting Room 06, 1/F, Building 1E, Hong Kong Science Park, N.T., Hong Kong at 8:00 p.m. Hong Kong Time on December 2, 2021 (7:00 a.m. Eastern Standard Time on December 2, 2021 / 12:00 p.m. Greenwich Mean Time on December 2, 2021 / 1:00 p.m. Central European Time on December 2, 2021).\n\nShareholders of record as of October 6, 2021 are entitled to receive notice of and vote at the annual general meeting. Aptorum filed its annual report on Form 20-F, including its audited financial statements for the fiscal year ended December 31, 2020, with the U.S. Securities and Exchange Commission (the \"SEC\") on April 19, 2021. Aptorum Group's annual report on Form 20-F can be accessed in the investor section of Aptorum's website at www.aptorumgroup.com, as well as on the SEC's website at www.sec.gov. Shareholders may request a meeting notice, proxy card or hard copy of the annual report on Form 20-F free of charge by contacting [email protected].\n\nAbout Aptorum Group\n\nAptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of Aptorum is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases; and (ii) the co-development of a novel molecular-based rapid pathogen identification and detection diagnostics technology with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore’s Agency for Science, Technology and Research.\n\nFor more information about Aptorum Group, please visit www.aptorumgroup.com.\n\nDisclaimer and Forward-Looking Statements\n\nThis press release does ...